Skip to content
CancerIndex

Publication

Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer.

Shengbai Xue, Haiyan Xu, Jingyu Ma, Yanling Wang, Wenxin Lu, Jiujie Cui, Liwei Wang

Cancer lettersSep 28, 2026PMID 42303056doi:10.1016/j.canlet.2026.218684 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 29, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260929-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Pancreatic ductal adenocarcinoma (PDAC) is highly aggressive, with KRAS mutations, particularly KRAS G12D, present in the majority of cases. While development of KRAS G12D inhibitors is rapid, acquired resistance remains a major clinical challenge. Therefore, in this study, we aimed to evaluate the…

Read on PubMed

Linked entities

Linked entities (2)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 1

Candidate 1

Registered trialsNCT06520488

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.